We are live on ! Find out more
Jacobs Levy Equity Management

Jacobs Levy Equity Management Portfolio holdings

AUM $23.8B
1-Year Est. Return 25.4%
This Fund
S&P 500
This Quarter Est. Return
+0.61%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$8.15B
AUM Growth
+$921M
Cap. Flow
+$973M
Cap. Flow %
11.94%
Top 10 Hldgs %
16.27%
Holding
1,064
New
127
Increased
460
Reduced
259
Closed
156

Top Buys

Rank Stock Value
1
QCOM icon
Qualcomm
QCOM
+$86.3M
2
DD icon
DuPont de Nemours
DD
+$57.9M
3
MSFT icon
Microsoft
MSFT
+$49.7M
4
GILD icon
Gilead Sciences
GILD
+$47.8M
5
F icon
Ford
F
+$39.9M

Top Sells

Rank Stock Value
1
BA icon
Boeing
BA
+$71M
2
TJX icon
TJX Companies
TJX
+$53.3M
3
INTU icon
Intuit
INTU
+$38.1M
4
COST icon
Costco
COST
+$34.3M
5
TWTR
Twitter, Inc.
TWTR
+$17.7M

Sector Composition

Rank Sector Weight
1 Technology 18.42%
2 Financials 17.1%
3 Consumer Discretionary 13.09%
4 Healthcare 12.19%
5 Industrials 10.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EGY icon
901
Vaalco Energy
EGY
$594M
$57K ﹤0.01%
27,933
EGIO
902
DELISTED
Edgio, Inc. Common Stock
EGIO
$50K ﹤0.01%
411
-63
-13% -$6.65K
COGT icon
903
Cogent Biosciences
COGT
$6.79B
$48K ﹤0.01%
8,249
-2,945
-26% -$23.9K
HSDT icon
904
Solana Company
HSDT
$95.2M
0
NCSM icon
905
NCS Multistage Holdings
NCSM
$124M
$46K ﹤0.01%
+1,151
New +$58.5K
SRGA
906
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$45K ﹤0.01%
525
-1,497
-74% -$160K
NH
907
DELISTED
NantHealth, Inc
NH
$36K ﹤0.01%
3,389
+20
+0.6% +$178
LUMO
908
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$26K ﹤0.01%
+1,824
New +$26.8K
AAT
909
American Assets Trust
AAT
$1.49B
-6,500
Closed -$306K
ABUS icon
910
Arbutus Biopharma
ABUS
$865M
-30,593
Closed -$64K
AHT
911
Ashford Hospitality Trust
AHT
$21M
-301
Closed -$883K
AKBA icon
912
Akebia Therapeutics
AKBA
$327M
-152,461
Closed -$738K
AL
913
DELISTED
Air Lease Corp
AL
-6,330
Closed -$262K
ALV icon
914
Autoliv
ALV
$8.6B
-3,380
Closed -$238K
AMGN icon
915
Amgen
AMGN
$203B
-84,190
Closed -$15.5M
ANDE icon
916
Andersons Inc
ANDE
$2.65B
-15,833
Closed -$431K
ANIK icon
917
Anika Therapeutics
ANIK
$199M
-9,768
Closed -$397K
AROC icon
918
Archrock
AROC
$6.33B
-184,534
Closed -$1.96M
ARWR icon
919
Arrowhead Research
ARWR
$12.1B
-33,500
Closed -$888K
AVGO icon
920
Broadcom
AVGO
$1.82T
-444,270
Closed -$12.8M
BJ icon
921
BJs Wholesale Club
BJ
$11.9B
-145,530
Closed -$3.84M
BMRN icon
922
BioMarin Pharmaceuticals
BMRN
$11.5B
-104,970
Closed -$8.99M
CACI icon
923
CACI
CACI
$10.8B
-6,550
Closed -$1.34M
CC icon
924
Chemours
CC
$2.59B
-141,324
Closed -$3.39M
CCI icon
925
Crown Castle
CCI
$32.7B
-9,550
Closed -$1.25M

Similar funds

Jacobs Levy Equity Management's Q3 2019 Portfolio in Review

As of Q3 2019, Jacobs Levy Equity Management held 1,064 positions worth $8.15B, up 13% from $7.23B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Jacobs Levy Equity Management deployed $973M of net new capital in Q3 2019, opening 127 new positions and adding to 460 existing holdings. Its largest new stake was Qualcomm: 1,146,127 shares worth $87.4M.

By sector, the portfolio is most concentrated in Technology at 18% of assets, down from 19% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was Boeing, an estimated $71M trimmed.

  • Jacobs Levy Equity Management's largest Q3 2019 buy was Qualcomm: 1,146,127 shares worth $87.4M.
  • Jacobs Levy Equity Management added most to DuPont de Nemours in Q3 2019, an estimated $57.9M increase.
  • Jacobs Levy Equity Management's biggest Q3 2019 reduction was Boeing, cutting an estimated $71M.
  • Jacobs Levy Equity Management fully exited TJX Companies in Q3 2019, selling an estimated $53.3M.
  • Jacobs Levy Equity Management's ten largest holdings make up 16% of its $8.15B portfolio in Q3 2019.
  • Jacobs Levy Equity Management opened 127 new positions and closed 156 in Q3 2019.
  • Jacobs Levy Equity Management's portfolio value rose 13% quarter-over-quarter to $8.15B.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2019, filed 14 Nov 2019.